Dose-escalated radiation does not benefit patients with low-risk prostate cancer
the ONA take:
According to a new study published online ahead of print this week in JAMA Oncology, researchers have found that higher radiation dose is associated with improved survival rates among men with medium- and high-risk prostate cancer. However, this association was not observed in patients with low-risk disease.
For the study, researchers analyzed data from 42,481 men with prostate cancer included in the National Cancer Database. Of those, 12,229 had low-risk disease, 16,714 had intermediate-risk disease, and 13,538 had high-risk prostate cancer. Patients were all diagnosed between 2004 and 2006 and received either standard-dose external-beam radiation therapy or dose-escalated radiation.
Results showed that higher dose radiotherapy was associated with increased survival in those with intermediate- and high-risk disease, but not in those with low-risk disease. The findings suggest that aggressive radiotherapy may not be beneficial in men with low-risk prostate cancer, adding to the evidence that watchful waiting or active surveillance may be better for these patients.
Higher radiation dose is associated with improved survival rates among men with medium- and high-risk prostate cancer.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|